(secondQuint)Papilloma Virus Vaccine Therapy in Treating Young Patients With Recurrent Papilloma of the Larynx.

 OBJECTIVES: I.

 Determine the immune response in patients with juvenile papilloma of the larynx treated with autogenous vaccine derived from each patient's own tumor.

 OUTLINE: Patients receive autogenous papilloma vaccine intradermally and subcutaneously weekly for 20 weeks.

 PROJECTED ACCRUAL: Not specified.

 Papilloma Virus Vaccine Therapy in Treating Young Patients With Recurrent Papilloma of the Larynx@highlight

RATIONALE: Vaccines made from papilloma virus cells may make the body build an immune response to and kill papilloma cells.

 PURPOSE: Phase II trial to study the effectiveness of papilloma virus vaccine in treating young patients with recurrent papilloma of the larynx.

